Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
about
HIV/AIDS and lipodystrophy: implications for clinical management in resource-limited settingsA risk-factor guided approach to reducing lactic acidosis and hyperlactatemia in patients on antiretroviral therapyIncidence of treatment-limiting toxicity with stavudine-based antiretroviral therapy in Cambodia: a retrospective cohort studyStavudine toxicity in adult longer-term ART patients in Blantyre, MalawiIncidence and predictors of first line antiretroviral regimen modification in western KenyaLongitudinal lactate levels from routine point-of-care monitoring in adult Malawian antiretroviral therapy patients: associations with stavudine toxicitiesA longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects.Quality of life in individuals living with HIV/AIDS attending a public sector antiretroviral service in Cape Town, South Africa.When to start antiretroviral therapy: the need for an evidence base during early HIV infectionIncidence and determinants of nevirapine and efavirenz-related skin rashes in West Africans: nevirapine's epitaph?Sex differences in the incidence of peripheral neuropathy among Kenyans initiating antiretroviral therapyThe development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy.New and emerging agents in the management of lipodystrophy in HIV-infected patients.Pharmacovigilance for antiretroviral drugs in Africa: lessons from a study in Abidjan, Cote d'Ivoire.HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury.Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South AfricaImproved survival in HIV treatment programmes in AsiaVirological failure of staggered and simultaneous treatment interruption in HIV patients who began Efavirenz-based regimens after allergic reactions to nevirapine.Acute pancreatitis in HIV/AIDS patients: an issue of concern.Effects of a reduced dose of stavudine on the incidence and severity of peripheral neuropathy in HIV-infected adults in South AfricaIncreases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South AfricaHyperlactatemia in a group of HIV patients living in Yaounde-Cameroon.Brief Report: Decentralizing ART Supply for Stable HIV Patients to Community-Based Distribution Centers: Program Outcomes From an Urban Context in Kinshasa, DRC.Has the phasing out of stavudine in accordance with changes in WHO guidelines led to a decrease in single-drug substitutions in first-line antiretroviral therapy for HIV in sub-Saharan Africa?In silico study supports the efficacy of a reduced dose regimen for stavudine.Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir.A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.Nevirapine-associated toxicity in clinical practice in Buenos Aires, Argentina.The prevalence of renal impairment among adults with early HIV disease in Blantyre, Malawi.
P2860
Q28088839-92FBC7D7-E203-4397-8D16-5CA0CC467A28Q28477707-05C31F3D-EB3B-469B-98F8-BF21078964C5Q28480421-63211332-051E-434B-A6D9-BAF695F22A84Q28481581-ABC74453-3712-4214-9114-AD8DBD135AD1Q28541822-61A47F62-30FC-4442-97CE-26F021BD7CE6Q33621094-AB8D850C-2294-4E5B-AAAC-4A04BF77F9A6Q34020969-9FBB69DB-CB4B-4EC9-97F8-1D124529CBABQ34486279-9153089E-A59E-4F3E-8E08-B400D1567F43Q34773308-FF63E28E-E952-4C61-A8C7-903A1AFD4B4DQ35146943-CB580EB7-5654-4CB2-AAD5-A3B4352D5479Q35164547-1AEB2F69-08EB-4109-B851-7E2A3EE92EE3Q35552675-9446065A-DC74-4E8B-9E55-3EA0D845594EQ35557229-0C400396-419B-4215-A694-EB49CEF25F06Q35582624-A60B33FF-31A5-4862-96B2-596164310A01Q35852627-387A6878-30FA-401F-9132-716E4170F1EFQ35856520-D3509AF4-DB6B-4DD4-AA80-C7F9E3EE0B09Q35951760-A991AFC1-6A7F-4802-81F1-F9C62615C780Q36621432-54B25F13-B74D-430D-B92B-467362E048C5Q36817085-877CE720-1065-466A-8281-CCCC2A6BF9A4Q36870758-CC0F9A70-54E0-48A8-B095-A9459A10D2D1Q37330398-D33401DF-A8CC-42A6-AEBE-AC72C32E0F49Q37506855-5E3E3108-949E-4A56-A32D-3DA7E6C141B6Q37639072-B54ACAAA-905B-461B-8E44-5DDD2D640F5DQ38404966-D22B9CFE-81CE-45D0-BE5F-6888985B30AEQ41819035-4E9A7830-1430-4513-A7B2-6440FB0C74B1Q42234057-7B74AB1D-9F9B-4E35-9AC7-DA661B5CDE3EQ42249729-DF557A66-5CE4-4C50-987A-4FF8A7C5EF8DQ42869234-9C6D9E5A-B464-4F53-AEDC-21E2AE89C4B9Q46234249-4DF06ED2-E2CC-45E4-877B-CA78AC3D0DAF
P2860
Stavudine- and nevirapine-related drug toxicity while on generic fixed-dose antiretroviral treatment: incidence, timing and risk factors in a three-year cohort in Kigali, Rwanda.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@en
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@nl
type
label
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@en
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@nl
prefLabel
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@en
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@nl
P2093
P1476
Stavudine- and nevirapine-rela ...... year cohort in Kigali, Rwanda.
@en
P2093
Edi F Atté
Freya Rasschaert
Jules Mugabo
Rony Zachariah
P304
P356
10.1016/J.TRSTMH.2009.07.009
P577
2009-09-03T00:00:00Z